Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

EUROPACE Raises Remote Monitoring Profile
"Moving to a more continuous follow-up approach would have the tremendous advantages of enhancing patient safety, decreasing physician and nurse work load, and allowing health staff to focus on medical emergencies," urged Professor Angelo Auricchio, from the European Heart Rhythm Association (EHRA) and official spokesperson of the European Society of Cardiology (ESC), adding that such systems may have the additional advantage of being more cost effective for health care providers.
generic viagra online
Changing Paradigms In Hereditary Angioedema: Pathophysiology, Diagnosis And Treatment
Hereditary angioedema (HAE) is an autosomal dominant disease affecting between 4,000 and 10,000 people in the United States. HAE causes recurrent attacks of intense localized edema involving the skin, airway, and visceral organs. While chronic therapy with attenuated androgens or plasmin inhibitors has been the mainstay of HAE therapy, many new therapies for prophylaxis and acute treatment are on the horizon. It is important for physicians to understand the diagnostic strategies in HAE as well as the conventional and emerging therapeutic options available for HAE prophylaxis and acute attacks.
News of the day
Limited Data Suggest Possible Association Between Agent Orange Exposure And Ischemic Heart Disease And Parkinson's Disease In Vietnam Veterans
A new report from the Institute of Medicine finds suggestive but limited evidence that exposure to Agent Orange and other herbicides used during the Vietnam War is associated with an increased chance of developing ischemic heart disease and Parkinson"s disease for Vietnam veterans. The report is the latest in a congressionally mandated series by the IOM that every two years reviews the evidence about the health effects of these herbicides and a type of dioxin -- TCDD -- that contaminated some of the defoliants.
Diagnostics

Lymphoma Research Funded By Millennium Pharmaceuticals Inc./Lymphoma Research Foundation

The Lymphoma Research Foundation (LRF) is pleased to announce that the 2009 Millennium Pharmaceuticals, Inc./Lymphoma Research Foundation Clinical Investigator Career Development Award has been awarded to Kai Fu, MD, PhD, Associate Professor at the Nebraska Medical Center in Omaha, Nebraska. Lymphoma, the most common type of blood cancer, is broadly categorized into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). According to a 2008 report from the World Health Organization, there are six types of HL and over 61 types of NHL; many of which are rare diseases. A member of LRF"s Mantle Cell Lymphoma Consortium (MCLC), Dr. Fu"s work will focus on mantle cell lymphoma (MCL), an aggressive malignant B-cell form of non-Hodgkin lymphoma (NHL). Mantle cell lymphoma is a rare form of NHL accounting for 6 percent of all new diagnoses of NHL or approximately 3,000 new cases per year in the United States. Mantle cell usually affects men over 60 and is frequently diagnosed as a Stage IV disease, often present in lymph nodes above and below the diaphragm and in most cases involves the gastrointestinal tract and bone marrow. MCL is characterized by over expression of the gene cyclin D1 due to a chromosomal translocation. A subset of MCL also expresses higher levels of a group of small RNA molecules, called miR-17~92. Dr. Fu and his co-workers have found that higher expression of miR-17~92 is directly correlated with poorer patient survival. These findings indicate that higher miR-17~92 expression induces abnormal activation of a pathway in tumor cells that leads to increased resistance to standard chemotherapy. Dr. Fu will conduct a pre-clinical study to determine whether suppression of miR-17~92 will improve the effect of chemotherapy. His study will thus provide a novel approach to treating MCL patients. "Dr. Fu"s elegant proposal explores a new avenue for understanding MCL and identifying potential therapeutic targets. We are delighted that Dr. Fu has chosen MCL as the focus of his Clinical Career Development Project," stated Michael Williams, MD, Director, Hematologic Malignancy Program - University of Virginia and Chair of LRF"s Mantle Cell Consortium. The 3-year Clinical Investigator Career Development Award is designed to fund training of clinicians who will participate in developing new therapeutics and diagnostic tools for lymphoma. The focus of the training is to prepare clinicians to design and administer clinical studies in lymphoma and to take on the primary responsibilities for clinical trial design, protocol writing, Institutional Review Board (IRB) submission, and publication. Dr. Fu will be pursuing a Career Development Plan with the guidance of his mentor, Dr. Wing Chan, Co-Director, Center for Lymphoma and Leukemia Research, at the University of Nebraska Medical Center, Omaha, NE. Dr. Fu will be supported by a grant of $300K over 3 years to accomplish his research project. The LRF thanks Millennium Pharmaceuticals, Inc./The Takeda Oncology Company for their generous support of this grant. "We are proud to be able to support lymphoma research through grants such as this one, and we are hopeful that the work we support may someday be a significant contribution to the discovery of new methods for treating blood cancer," said Dixie-Lee Esseltine, MD, Vice President, Global Medical Affairs, Millennium. "The Millennium Pharmaceuticals, Inc./Lymphoma Research Foundation clinical Investigator Career Development Award is supported by an independent grant from Millennium Pharmaceuticals, Inc. (Millennium). Millennium neither controlled nor influenced the nomination or selection of any award recipient." About the Mantle Cell Lymphoma Consortium (MCLC) Established by LRF in January 2005, the MCLC is comprised of more than 100 laboratory and clinical scientists from North America and Europe who focus their research on mantle cell lymphoma (MCL). The Consortium is designed to accelerate the understanding and treatment of MCL by bringing together these lead investigators, funding innovative studies and creating important res such as the MCL website and cell bank. About the Lymphoma Research Foundation The Lymphoma Research Foundation (LRF) is the nation"s largest voluntary health organization devoted exclusively to funding lymphoma research and providing patients and healthcare professionals with critical information on the disease. LRF"s mission is to eradicate lymphoma and serve those touched by this disease. As of June 30, 2008, LRF has funded over $37 million in lymphoma-specific research. The Foundation is the world"s largest private funder of mantle cell lymphoma research. LRF also provides a comprehensive series of programs and services for patients, survivors and loved ones affected by lymphoma, including our toll-free Lymphoma Helpline and Clinical Trials Information Service, in-person patient education programs, web casts/teleconferences and support services. Marion F. Swan Lymphoma Research Foundation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009